← Eichor
Condition: Biliary Tract Neoplasms Immunotherapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Biliary Tract Neoplasms Immunotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06864481Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06230471Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07025174A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine i
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07679399Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06001658Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined wi
Phase N/A · 2 location(s) · Zhongda Hospital · NCT06849193A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects W
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05849480Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Trac
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07636798A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT06349044Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Chola
Phase 2 · 1 location(s) · Jinbo Yue · NCT07030140Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07159204Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07670273Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabili
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT05451043MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Phase 2 · 11 location(s) · Centre Hospitalier Universitaire de Besancon · NCT07036380Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cance
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06564623Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expressio
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07704177
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.